Mitoxantrone dihydrochloride, Type II topoisomerase inhibitor

Alternative names

1,8-cineole 2-exo-monooxygenase, 3-alkyladenine DNA glycosylase, 3-methyladenine DNA glycosidase, 3MG_HUMAN, A830040C14Rik, AAG, ACLS, ADPG, AI838772, AIS, ANDR_HUMAN, AP endonuclease 1, AP endonuclease class I, AP lyase, APE, APEN, APEX, APEX nuclease, APEX nuclease (multifunctional DNA repair enzyme) 1, APEX1_HUMAN, APNG, APOPAIN, APX, AR, AR8, ARO, ARO1, AW493413, Albendazole monooxygenase, Albendazole sulfoxidase, Alkyladenine DNA glycosylase, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Antigen NY-CO-13, Apex nuclease 1, Apoptotic protease Mch-3, Apurinic endonuclease, Apurinic-apyrimidinic endonuclease 1, Apurinic/apyrimidinic (abasic) endonuclease, Apurinic/apyrimidinic endonuclease 1, Apurinic/apyrimidinic exonuclease, Aromatase, Atherosclerosis, susceptibility to, included, BAR, BCC7, BLM_HUMAN, BS, BXR, Beta-interferon, Bile acid receptor, Bloom syndrome, Bloom syndrome RecQ helicase like, Bloom syndrome protein, CAR, CAR BETA, CARA, CASP3_HUMAN, CASP7_HUMAN, CC3, CMH-1, CP19A_HUMAN, CP33, CP34, CP3A4_HUMAN, CPP-32, CPP32B, CPV1, CRA36.1, CYAR, CYP19, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIIA3, CYPIIIA4, CYPXIX, Car 1, Casp3a, Caspase 3, apoptosis-related cysteine peptidase, Caspase 3, apoptosis-related cysteine protease, Caspase 3, apoptosis-related cysteine protease a, Caspase 7, Caspase 7 apoptosis related cysteine peptidase, Caspase-3, Caspase-3 subunit p12, Caspase-7 subunit p11, Cellular tumor antigen p53, Constitutive activator of retinoid response, Constitutive active response, Constitutive androstane receptor, Cyp19a1, Cysteine protease CPP32, Cytochrome P-450AROM, Cytochrome P450 19A1, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 19, subfamily A, polypeptide 1, Cytochrome P450, subfamily XIX (aromatization of androgens), Cytochrome P450-PCN1, DHTR, DINB protein, DINB1, DINP, DKFZp686N23123, DNA binding protein, DNA damage inducible protein b, DNA directed DNA polymerase beta, DNA helicase, DNA helicase RecQ like type 2, DNA pol beta, DNA polymerase beta, DNA polymerase beta subunit, DNA polymerase eta, DNA polymerase iota, DNA polymerase kappa, DNA-(apurinic or apyrimidinic site) lyase, DNA-(apurinic or apyrimidinic site) lyase, mitochondrial, DNA-3-methyladenine glycosylase, DPOLB_HUMAN, Deoxyribonuclease (apurinic or apyrimidinic), Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), DinB homolog 1 (E. coli), EC 3.4.22.56, EC 4.2.99.18, ER, ER-alpha, ER-beta, ERK-2, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ERT1, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, EXP, EXP35, EXP40, EXP42, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen synthase, Estrogen synthetase, Estrogen-related receptor alpha, Estrra, Eta 2, Extracellular signal-regulated kinase 2, FLJ11090, FLJ16395, FLJ21978, FLJ92943, Farnesoid X-activated receptor, Farnesol receptor HRR-1, Fibroblast interferon, GCN5 general control of amino acid synthesis 5 like 2, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Glioma associated oncogene family zinc finger 3, Glucocorticoid inducible P450, HDL cholesterol, augmented response of, to hormone replacement, included, HLP, HRR 1, HSMPP8, HUMARA, HYSP1, Human Apurinic endonuclease 1, ICE-LAP3, ICE-like apoptotic protease 3, ICE3, IFB, IFF, IFN-beta, IFNB 1, IFNB_HUMAN, IMD42, Interferon beta, Interferon beta 1 fibroblast, Interferon beta precursor, KD, KIAA0428, Kennedy disease (KD), LFS1, LICE, LICE2, M-phase phosphoprotein 8, M-phase phosphoprotein, mpp, M-phase phosphoprotein, mpp8, MAP kinase 1, MAP kinase 2, MAP kinase isoform p42, MAPK 1, MB67, MBNL, MBNL protein, MBNL1_HUMAN, MCH3, MGC104252, MGC104309, MGC112732, MGC125976, MGC126616, MGC126680, MGC129539, MGC131618, MGC131620, MGC139790, MGC96956, MGC97144, MK01_HUMAN, MPHOSPH8, MPP8_HUMAN, Microsomal monooxygenase, Mitogen-activated protein kinase 1, Mitogen-activated protein kinase 2, Mpg, Multifunctional DNA repair enzyme, Muscleblind 41kD isoform, Muscleblind like, Muscleblind like splicing regulator 1, Muscleblind-like protein 1, Mutant tumor protein 53, Myocardial infarction, susceptibility to, included, N methylpurine DNA glycosirase, N-methylpurine-DNA glycosylase, NF 25, NR1B1, NR1C3, NR1F3, NR1I2_HUMAN, NR1I3_HUMAN, NR3A1, NR3A2, NR3B1, NR3C3, NR3C4, Nifedipine oxidase, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor ROR-gamma, Nuclear receptor RZR-gamma, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group C member 3, Nuclear receptor subfamily 1 group F member 3, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 3, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, ONR 1, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000162543, OTTHUMP00000165052, OTTHUMP00000165053, OTTHUMP00000165054, OTTHUMP00000198350, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Oncogene GLI3, Oncogene PIM 1, Orphan nuclear receptor MB67, Orphan nuclear receptor NR1I3, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P 450AROM, P38, P41, P450 III steroid inducible, P450 PCN1, P450, family III, P450C3, P53_HUMAN, PAP A, PAPB, PAR, PAR q, PARP cleavage protease, PGR, PIG11, PIG16, PIM, PIM1_HUMAN, POLH_HUMAN, POLI_HUMAN, POLK_HUMAN, POLQ, PPAR-gamma, PPARG2, PPARG_HUMAN, PPD IV, PR, PRA, PRB, PRGR_HUMAN, PRKM 2, PRKM1, PRR, Peroxisome proliferator activated receptor gamma 2, Peroxisome proliferator-activated receptor gamma, Phosphoprotein p53, Pim 1 kinase, Pim 1 oncogene, Pol B, Pol beta, Polymerase (DNA directed) beta, Polymerase (DNA directed) iota, Polymerase (DNA directed) kappa, Pregnane X receptor, Procaspase3, Progesterone receptor, Progestin receptor form A, Progestin receptor form B, Proliferation inducing protein 11, Proliferation inducing protein 16, Protein Yama, Proto-oncogene serine/threonine-protein kinase Pim-1, Proviral integration site 1, Proviral integration site 2, Quinine 3-monooxygenase, RAD 30B, RAD30, RAD30 homolog A, RAD30 homolog B, RAD30, S. cerevisiae, homolog of, RAD30A, RAD3OB, RAR, RAR related orphan nuclear receptor variant 2, RAR related orphan receptor C, isoform a, RAR related orphan receptor gamma, RAR-alpha, RAR-related orphan receptor C, RARA_HUMAN, RARalpha1, RECQ 2, RECQ like, RECQL 2, RECQL 3, REF 1 protein, REF-1, RIP 14, RNESTROR, RORG_HUMAN, RP11-523H24.1, RP24-311F12.2, RXR-interacting protein 14, RZR GAMMA, RZRG, RecQ protein-like 3, RecQ-like type 2, Redox factor-1, Retinoic acid binding receptor gamma, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, Retinoid X receptor-interacting protein 14, Retinoid-related orphan receptor-gamma, Rorc, SBMA, SCA-1, SCAN1, SMAX1, SREBP cleavage activity 1, SXR, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, Steroid hormone receptor ERR1, TFM, TOR, TRP53, TYDP, TYDP1_HUMAN, Taurochenodeoxycholate 6-alpha-hydroxylase, Testicular Feminization (TFM), Tp53, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Transformation related protein 53, Triplet-expansion RNA-binding protein, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Twa3, Two hybrid-associated protein 3 with RanBPM, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, XP V, Xeroderma pigmentosum variant type protein, Yama, Yama protein, Zinc finger protein GLI 3, androgen receptor splice variant 4b, anpg, constitutive active receptor, constitutive androstane nuclear receptor variant 2, constitutive androstane nuclear receptor variant 3, constitutive androstane nuclear receptor variant 4, constitutive androstane nuclear receptor variant 5, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, hERR1, mldy, orphan nuclear hormone receptor, p42-MAPK, p53 tumor suppressor, pim 1 kinase 44 kDa isoform, pim 1 oncogene (proviral integration site 1), polymerase DNA directed eta, polymerase, DNA, kappa, pregnane X nuclear receptor variant 2, protein kinase, mitogen-activated, 1, protein kinase, mitogen-activated, 2, protein tyrosine kinase ERK2, tumor antigen p55, type 2